"Efficacy and safety of peginterferon ?-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F11%3A0070" target="_blank" >RIV/61383082:_____/11:0070 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >http://dx.doi.org/10.1097/MEG.0b013e32834b326b</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >10.1097/MEG.0b013e32834b326b</a>

Jazyk výsledku

angličtina

Název v původním jazyce

"Efficacy and safety of peginterferon ?-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Popis výsledku v původním jazyce

All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon ?-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe.

Název v anglickém jazyce

"Efficacy and safety of peginterferon ?-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Popis výsledku anglicky

All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon ?-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European journal of gastroenterology & hepatology 2011

ISSN

0954-691X

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1004-1010

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—